Publication & Citation Trends
Publications
166 total
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.
Cited by 2
Semantic Scholar
1359: Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16
Cited by 0
Semantic Scholar
OC-0433 GETUG-AFU 22 phase II randomized trial : final results on clinical outcomes with immediate SRT
Cited by 1
Semantic Scholar
GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
Cited by 6
Semantic Scholar
1198 A dual targeting CD33/CD123 NANOBODY® T-cell engager with potent anti-AML activity and a manageable safety profile OA
Cited by 0
Semantic Scholar
Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia OA
Cited by 1
Semantic Scholar
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment OA
Cited by 13
Semantic Scholar
An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities OA
Cited by 25
Semantic Scholar
Late toxicity and quality of life from GETUG-AFU 22 study.
Cited by 1
Semantic Scholar
Research Topics
Prostate Cancer Diagnosis and Treatment
(76)
Prostate Cancer Treatment and Research
(66)
Monoclonal and Polyclonal Antibodies Research
(35)
Glycosylation and Glycoproteins Research
(31)
Advanced Radiotherapy Techniques
(29)
Affiliations
Pfizer (United States)
Sanofi (France)
Université de Poitiers
Centre de Radiothérapie Bayard
Centre Georges François Leclerc